Inhibikase Therapeutics Inc (IKT) Stock Price, Quote & News

Company Profile

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to im...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 295 3800

Website: www.inhibikase.com

Address:

1000 N. West Street, Suite 1200, Wilmington, United States

BiotechJedi1728 Aug. 19 at 3:20 PM

$IKT This should be popping more today with the rest of the small cap biotech.

0 · Reply

TJC1791 Aug. 13 at 1:16 AM

$IKT I asked ChatGPT to provide more information regarding the recent poster presentation mentioned in the latest PR. Here’s the response. It feels quite balanced and whilst I was a little concerned around the point about an 18 fold decrease in c-kit inhibition, the bottom line summary is quite encouraging. Not investment advice. https://chatgpt.com/share/6a7ced1b-5d1c-83ec-a90a-9a48d01a8e61

1 · Reply

Mjf04288 Aug. 11 at 8:16 PM

$IKT https://www.inhibikase.com/news/press-releases/detail/145/inhibikase-therapeutics-announces-second-quarter-2026

0 · Reply

BiotechJedi1728 Aug. 5 at 11:02 AM

$IKT

0 · Reply

BiotechJedi1728 Aug. 4 at 8:04 PM

$IKT This is how we do it!

0 · Reply

Mjf04288 Jul. 28 at 10:48 PM

$IKT It looks like Black Rock increased their position

0 · Reply

freddieg24 Jul. 28 at 3:00 PM

$IKT if this hits the low end of a price target before earnings this could happen a lot sooner than everyone thinks watch closely up until the 14th for any pull backs but this is gaining some good support and traction…. who knows whats on the 2026 horizon… we definitely wont get any trial results until early/mid next year (stating the obvious) but this is everything a bullish biotech stock needs

0 · Reply

PepsiLover Jul. 27 at 3:11 PM

$IKT This stock is so stable even with routine P&D every few months lol, really wish this one gonna work out next year.

0 · Reply

Avocado_smash Jul. 27 at 12:37 PM

$IKT PT 2.68++

0 · Reply

LSOTradingDesk Jul. 26 at 9:13 AM

$IKT Worth watching for RSI to actually turn up through 40 before treating this as an entry zone — right now it's still in the falling phase of the pullback.

0 · Reply

Inhibikase Therapeutics reports Q2 EPS (11c), consensus (9c)

Aug 11, 2026, 4:01 PM EDT - 7 days ago

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

Aug 11, 2026, 4:00 PM EDT - 7 days ago

Inhibikase Therapeutics Earnings release: Q2 2026

Aug 11, 2026, 4:00 PM EDT - 7 days ago

Inhibikase Therapeutics Quarterly report: Q2 2026

2026-07-23T12:16:10.000Z - 27 days ago

Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA

Jul 23, 2026, 8:00 AM EDT - 27 days ago

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

2026-07-16T21:05:22.000Z - 4 weeks ago

Inhibikase Therapeutics’ treatment of PAH granted FDA orphan designation

Jul 14, 2026, 8:00 AM EDT - 5 weeks ago

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

Jul 2, 2026, 4:01 PM EDT - 6 weeks ago

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-06-10T11:34:59.000Z - 2 months ago

Inhibikase Therapeutics initiated with an Outperform at Oppenheimer

May 20, 2026, 7:00 AM EDT - 3 months ago

Inhibikase Therapeutics Slides: Corporate presentation

May 12, 2026, 4:01 PM EDT - 3 months ago

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

May 12, 2026, 4:00 PM EDT - 3 months ago

Inhibikase Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:00 PM EDT - 3 months ago

Inhibikase Therapeutics Quarterly report: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Inhibikase Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Inhibikase Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Inhibikase Therapeutics Proxy statement: Proxy filing

2026-04-07T12:42:54.000Z - 4 months ago

Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study

Apr 7, 2026, 8:00 AM EDT - 4 months ago

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Apr 1, 2026, 7:00 AM EDT - 5 months ago

Inhibikase Therapeutics Slides: Corporate presentation

Mar 26, 2026, 4:01 PM EDT - 5 months ago

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

Mar 26, 2026, 4:00 PM EDT - 5 months ago

Inhibikase Therapeutics Annual report: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 5 months ago

Inhibikase Therapeutics Earnings release: Q4 2025

2026-03-04T12:41:55.000Z - 6 months ago

Inhibikase Therapeutics initiated with a Buy at Ladenburg

2026-03-04T11:48:05.000Z - 6 months ago

Inhibikase Therapeutics initiated with a Buy at Ladenburg

2026-01-21T11:31:15.000Z - 7 months ago

Inhibikase Therapeutics initiated with a Buy at BofA

2025-12-11T13:00:48.000Z - 8 months ago

Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald

2025-11-21T04:00:11.000Z - 9 months ago

Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45

Nov 20, 2025, 9:54 PM EST - 9 months ago

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

2025-11-20T21:50:22.000Z - 9 months ago

Inhibikase Therapeutics TBA Spot Secondary; reoffered at $1.45

2025-11-20T21:15:17.000Z - 9 months ago

Inhibikase announces common stock and warrants offering, no amount given

Nov 20, 2025, 4:12 PM EST - 9 months ago

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2025-11-20T21:11:51.000Z - 9 months ago

Inhibikase Therapeutics to advance IKT-001 to Phase 3 clinical study in PAH

Nov 20, 2025, 4:01 PM EST - 9 months ago

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Nov 20, 2025, 6:00 AM EST - 9 months ago

Inhibikase Therapeutics Slides: Corporate presentation

Nov 14, 2025, 4:01 PM EST - 9 months ago

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

Nov 14, 2025, 4:00 PM EST - 9 months ago

Inhibikase Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 9 months ago

Inhibikase Therapeutics Earnings release: Q3 2025

2025-08-19T12:15:43.000Z - 1 year ago

Inhibikase Therapeutics appoints Pigot as Chief Commercial, Strategy Officer

Aug 19, 2025, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

Aug 14, 2025, 4:50 PM EDT - 1 year ago

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Inhibikase Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Inhibikase Therapeutics Earnings release: Q2 2025

2025-06-20T21:10:07.000Z - 1 year ago

Inhibikase Therapeutics files $300M mixed securities shelf

Jun 20, 2025, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Registration statement: Registration Filing

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Proxy statement: Proxy Filing

May 14, 2025, 4:05 PM EDT - 1 year ago

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

May 14, 2025, 9:30 AM EDT - 1 year ago

Inhibikase Therapeutics Quarterly report: Q1 2025

May 14, 2025, 9:30 AM EDT - 1 year ago

Inhibikase Therapeutics Earnings release: Q1 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Proxy statement: Proxy Filing

May 12, 2025, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Proxy statement: Proxy Filing

May 2, 2025, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Proxy statement: Proxy Filing

2025-04-14T12:15:44.000Z - 1 year ago

Inhibikase Therapeutics announces appointment of McIntyre as CFO

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Mar 27, 2025, 5:00 PM EDT - 1 year ago

Inhibikase Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 5:00 PM EDT - 1 year ago

Inhibikase Therapeutics Annual report: Q4 2024

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

2025-02-24T13:15:39.000Z - 1 year ago

Inhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSO

Feb 24, 2025, 8:00 AM EST - 1 year ago

Inhibikase Announces Expansion of Senior Leadership Team

2025-02-18T13:26:26.000Z - 1 year ago

Inhibikase Therapeutics appoints Mark Iwicki as CEO

Feb 18, 2025, 8:00 AM EST - 1 year ago

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth

2025-02-12T11:10:56.000Z - 1 year ago

Inhibikase Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

Jan 29, 2025, 6:30 PM EST - 1 year ago

Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study

Jan 10, 2025, 7:00 AM EST - 1 year ago

Inhibikase Therapeutics Registration statement: Registration Filing

Dec 3, 2024, 7:00 AM EST - 1 year ago

Inhibikase Therapeutics Registration statement: Registration Filing

Nov 18, 2024, 7:00 AM EST - 1 year ago

Inhibikase Therapeutics Registration statement: Registration Filing

Nov 18, 2024, 7:00 AM EST - 1 year ago

Inhibikase Therapeutics Proxy statement: Proxy Filing

Nov 14, 2024, 8:37 AM EST - 1 year ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

Nov 14, 2024, 8:30 AM EST - 1 year ago

Inhibikase Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

Inhibikase Therapeutics Quarterly report: Q3 2024

Nov 8, 2024, 7:00 AM EST - 1 year ago

Inhibikase Therapeutics Proxy statement: Proxy Filing

Oct 21, 2024, 9:05 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Oct 17, 2024, 9:00 AM EDT - 1 year ago

Inhibikase Therapeutics Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 9, 2024, 9:18 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Earnings Call Transcript: Q2 2024

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Quarterly report: Q2 2024

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Earnings release: Q2 2024

Aug 14, 2024, 4:25 PM EDT - 2 years ago

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Jun 21, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Proxy statement: Proxy Filing

Jun 20, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Proxy statement: Proxy Filing

Jun 18, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Registration statement: Registration Filing

Jun 17, 2024, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

Jun 10, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Proxy statement: Proxy Filing

Jun 5, 2024, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

May 20, 2024, 8:01 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

May 16, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Earnings Call Transcript: Q1 2024

May 16, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Quarterly report: Q1 2024

May 16, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Earnings release: Q1 2024

May 15, 2024, 8:00 PM EDT - 2 years ago

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

May 15, 2024, 8:45 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

May 9, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

May 9, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Registration statement: Registration Filing

May 9, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Registration statement: Registration Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Registration statement: Registration Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Registration statement: Registration Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Registration statement: Registration Filing

Apr 18, 2024, 4:30 PM EDT - 2 years ago

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Proxy statement: Proxy Filing

Apr 3, 2024, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Earnings Call Transcript: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Earnings release: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Annual report: Q4 2023

Mar 27, 2024, 4:15 PM EDT - 2 years ago

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Mar 7, 2024, 8:30 AM EST - 2 years ago

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Feb 28, 2024, 4:05 PM EST - 2 years ago

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Feb 7, 2024, 7:55 AM EST - 2 years ago

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

Jan 29, 2024, 9:05 AM EST - 2 years ago

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

Jan 16, 2024, 4:05 PM EST - 2 years ago

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

Dec 7, 2023, 7:00 AM EST - 2 years ago

Inhibikase Therapeutics Slides: Investor Presentation

Dec 4, 2023, 8:35 AM EST - 2 years ago

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Nov 15, 2023, 8:00 AM EST - 3 years ago

Inhibikase Therapeutics Earnings Call Transcript: Q3 2023

Nov 15, 2023, 8:00 AM EST - 3 years ago

Inhibikase Therapeutics Quarterly report: Q3 2023

Nov 15, 2023, 8:00 AM EST - 3 years ago

Inhibikase Therapeutics Earnings release: Q3 2023

Nov 14, 2023, 4:30 PM EST - 3 years ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Nov 7, 2023, 9:28 AM EST - 3 years ago

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

Oct 16, 2023, 7:00 AM EDT - 3 years ago

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment

Oct 4, 2023, 8:30 AM EDT - 3 years ago

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

Aug 24, 2023, 8:30 AM EDT - 3 years ago

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib

Aug 22, 2023, 8:05 AM EDT - 3 years ago

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

Aug 21, 2023, 8:30 AM EDT - 3 years ago

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib

Aug 17, 2023, 8:30 AM EDT - 3 years ago

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro

Aug 15, 2023, 8:00 AM EDT - 3 years ago

Inhibikase Therapeutics Earnings Call Transcript: Q2 2023

Aug 15, 2023, 8:00 AM EDT - 3 years ago

Inhibikase Therapeutics Quarterly report: Q2 2023

Aug 15, 2023, 8:00 AM EDT - 3 years ago

Inhibikase Therapeutics Earnings release: Q2 2023

Aug 7, 2023, 8:05 AM EDT - 3 years ago

Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023

Jul 17, 2023, 4:05 PM EDT - 3 years ago

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

BiotechJedi1728 Aug. 19 at 3:20 PM

$IKT This should be popping more today with the rest of the small cap biotech.

0 · Reply

TJC1791 Aug. 13 at 1:16 AM

1 · Reply

Mjf04288 Aug. 11 at 8:16 PM

$IKT https://www.inhibikase.com/news/press-releases/detail/145/inhibikase-therapeutics-announces-second-quarter-2026

0 · Reply

BiotechJedi1728 Aug. 5 at 11:02 AM

$IKT

0 · Reply

BiotechJedi1728 Aug. 4 at 8:04 PM

$IKT This is how we do it!

0 · Reply

Mjf04288 Jul. 28 at 10:48 PM

$IKT It looks like Black Rock increased their position

0 · Reply

freddieg24 Jul. 28 at 3:00 PM

0 · Reply

PepsiLover Jul. 27 at 3:11 PM

$IKT This stock is so stable even with routine P&D every few months lol, really wish this one gonna work out next year.

0 · Reply

Avocado_smash Jul. 27 at 12:37 PM

$IKT PT 2.68++

0 · Reply

LSOTradingDesk Jul. 26 at 9:13 AM

$IKT Worth watching for RSI to actually turn up through 40 before treating this as an entry zone — right now it's still in the falling phase of the pullback.

0 · Reply

BiotechJedi1728 Jul. 24 at 9:28 PM

$IKT Whoever sold 60,000 shares at 2.40 will be regretting that Monday.

1 · Reply

Goodguy22 Jul. 24 at 8:40 PM

Bought $IKT shares at 2.37

0 · Reply

Mjf04288 Jul. 24 at 8:01 PM

$IKT Dang!

0 · Reply

BiotechJedi1728 Jul. 24 at 2:56 PM

$IKT Feeling hella good so I am gonna keep on dancing !! 💃 🕺

0 · Reply

PepsiLover Jul. 23 at 7:48 PM

$IKT We breaking the cycle?

0 · Reply

Stock_Catcher Jul. 23 at 12:04 PM

$IKT Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

0 · Reply

GregK13 Jul. 20 at 12:18 AM

$IKT Pay attention to short interest here. It’s dropped massively!

2 · Reply

GregK13 Jul. 20 at 12:17 AM

$IKT This could easily bounce up hard on Monday morning opening for a great swing or day trade.

0 · Reply

PharmToBank Jul. 17 at 4:29 PM

$IKT I don't expect this will be a big catalyst as it was likely expected but it appears orphan drug designation was granted yesterday (not to be confused with FDA approved for orphan indication)

0 · Reply

BiotechJedi1728 Jul. 15 at 1:12 PM

$IKT $2 could be new floor. Maybe she is curling up. Consolidating for another move up I hope.

0 · Reply

topstockalerts Jul. 14 at 5:24 PM

$IKT if this holds, could get interesting fast

0 · Reply

Zardiw Jul. 14 at 4:43 PM

#DDAmanda Chart on $KUST. Your thoughts? Also scanning: $NVNI $IKT $SHPH See more DDAmanda finds: https://DDAmanda.com/

0 · Reply

Market Cap	333.49M
Revenue (ttm)	0.00
Net Income (ttm)	-48.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	343,900
Avg Vol	856,940
Day's Range	N/A - N/A
Shares Out	139.54M
Stochastic %K	42%
Beta	0.95
Analysts	Strong Sell
Price Target	$6.00